Media headlines about Genomic Health (NASDAQ:GHDX) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Genomic Health earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.4191200357958 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Comparing Oncomed Pharmaceuticals (OMED) & Genomic Health (GHDX) (americanbankingnews.com)
- Genomic Health Inc (bloomberg.com)
- Genomic Health (GHDX) Raised to “Hold” at ValuEngine (americanbankingnews.com)
- Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : December 15, 2017 (finance.yahoo.com)
- Genomic Health drawing takeover interest; shares ahead 20% (seekingalpha.com)
Genomic Health (NASDAQ:GHDX) opened at $35.55 on Monday. Genomic Health has a 1 year low of $26.37 and a 1 year high of $35.57.
In other news, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total transaction of $149,700.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,379 shares of company stock worth $511,531. Corporate insiders own 46.20% of the company’s stock.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
What are top analysts saying about Genomic Health? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health and related companies.